H8A-MC-LZAZ - ClinicalTrials.gov - NCT02008357
H8A-MC-LZAZ - ClinicalTrials.gov - NCT02008357
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)
Participant must have good vein access, such that intravenous (IV) drug delivery or multiple blood draws would be able to be obtained
Participants must NOT
Participant must not be receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine
Participant must not have a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in longer than expected loss of consciousness
Participant must not have a history within the past 2 years of major depression or bipolar disorder
Participant must not have a history within the past 5 years of chronic alcohol or drug abuse/dependence
Participant must not have a known history of human immunodeficiency virus (HIV)
Trial Summary
Conditions the trial is for
At Risk For Alzheimer's
What the trial is testing?
Solanezumab (LY2062430), Placebo
Could I receive a Placebo?
yes
Enrollment Goal
1150
Trial Dates
February 2014 - January 2023
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)
Participant must have good vein access, such that intravenous (IV) drug delivery or multiple blood draws would be able to be obtained
Participants must NOT
Participant must not be receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine
Participant must not have a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in longer than expected loss of consciousness
Participant must not have a history within the past 2 years of major depression or bipolar disorder
Participant must not have a history within the past 5 years of chronic alcohol or drug abuse/dependence
Participant must not have a known history of human immunodeficiency virus (HIV)
Trial Summary
Conditions the trial is for
At Risk For Alzheimer's
What the trial is testing?
Solanezumab (LY2062430), Placebo
Could I receive a Placebo?
yes
Enrollment Goal
1150
Trial Dates
February 2014 - January 2023
Trial Phase
3
Trial Locations
Hide locations not currently recruiting